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Background: The central nervous system plays a vital role in the development of
hypertension, but the molecular regulatory mechanisms are not fully understood. This
study aimed to explore signaling in the paraventricular nucleus (PVN) which might
contribute to renal hypertension.
Methods: Renal hypertension model was established by five-sixth nephrectomy
operation (5/6Nx) in male Sprague Dawley rats. Ten weeks afterwards, they were
random assigned to no treatment, or intracerebroventricular injection (ICV) with
artificial cerebrospinal fluid, losartan [angiotensin II receptor type 1 (AT1R) antagonist],
farnesylthiosalicylic acid (Ras inhibitor), PD98059 (MEK inhibitor), or SB203580
(p38 inhibitor) and Z-DEVD-FMK (caspase-3 inhibitor). Before and after treatment,
physiological and biochemical indices were measured. Immunohistochemistry, western
blot and RT-PCR were applied to quantify key components of renin-angiotensin system,
apoptosis-related proteins, Ras-GTP, and MAPKs in the PVN samples. TUNEL assay
was used to measure the situ apoptosis in PVN.
Results: The 5/6Nx rats showed significantly elevated systolic blood pressure,
urinary protein excretion, serum creatinine, and plasma norepinephrine (p < 0.05)
compared to sham rats. The expression of angiotensinogen, Ang II, AT1R, p-ERK1/2,
or apoptosis-promoting protein Bax were 1.08-, 2.10-, 0.74-, 0.82-, 0.83-fold higher in
the PVN of 5/6Nx rats, than that of sham rats, as indicated by immunohistochemistry.
Western blot confirmed the increased levels of AT1R, p-ERK1/2 and Bax; meanwhile,
Ras-GTP and p-p38 were also found higher in the PVN of 5/6Nx rats, as well as the
apoptosis marker cleaved caspase-3 and TUNEL staining. In 5/6Nx rats, ICV infusion of
AT1R antagonist, Ras inhibitor, MEK inhibitor or caspase-3 inhibitor could lower systolic
blood pressure (20.8-, 20.8-, 18.9-, 14.3%-fold) together with plasma norepinephrine
(53.9-, 57.8-,63.3-, 52.3%-fold). Western blot revealed that blocking the signaling of
AT1R, Ras, or MEK/ERK1/2 would significantly reduce PVN apoptosis as indicated by
changes of apoptosis-related proteins (p < 0.05). AT1R inhibition would cause reduction
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in Ras-GTP and p-ERK1/2, but not vice versa; such intervention with corresponding
inhibitors also suggested the unidirectional regulation of Ras to ERK1/2.
Conclusion: These findings demonstrated that the activation of renin-angiotensin
system in PVN could induce apoptosis through Ras/ERK1/2 pathway, which then led
to increased sympathetic nerve activity and renal hypertension in 5/6Nx rats.
Keywords: paraventricular nucleus, apotosis, AT1R/Ras/ERK1/2, sympathetic activity, renal hypertension
INTRODUCTION
Increased incidence of chronic kidney disease has become a
major global public health problem (Schoolwerth et al., 2006).
Its primary risk factors are old age, diabetes, hypertension,
hyperlipidemia, and so forth, among which hypertension is
also the most common secondary disease (Bash et al., 2010;
Gansevoort et al., 2013). Hypervolemia and renin-angiotensin
system (RAS) activation are considered major determinants of
hypertension in chronic renal failure, and blood pressure can be
reduced by controlling these two factors (Nguy et al., 2013).
The main hormone generated by the RAS system is
angiotensin (Ang) II, which is produced by angiotensinogen
(AGT) cleavage (Griffin and Bidani, 2006). Ang II binding
to angiotensin II type 1 receptor robustly activates mitogen-
activated protein kinase (MAPK) intracellular signaling pathways
to adjust hypertension (Wei et al., 2008a). Three major terminal
effector kinases of the MAPK family include extracellular
signal regulated protein kinases 1 and 2 (ERK 1/2), stress-
activated protein kinase/c-Jun NH2-terminal kinases, and p38
MAPK (Johnson and Lapadat, 2002). MAPK signaling pathways
regulate a variety of cellular biological processes such as gene
expression, and cell proliferation, differentiation, survival, and
death, in normal developmental processes of the brain (Mielke
and Herdegen, 2000; Chang and Karin, 2001). Overactivation
of brain angiotensin-converting enzyme (ACE)–angiotensin II
(Ang II)–angiotensin II type 1 receptor (AT1R) axis has been
found to play a important role in the development and
maintenance of hypertension and then elevated oxidative stress
in brain and increased the activity of sympathetic nervous system
(Veerasingham and Raizada, 2003). Moreover, an increased
oxidative stress leads to the inward flow of Ca2+ in neurons,
thus activating proapoptotic mechanism and leading to neuronal
losses (Brown and Davis, 2002).
It is generally admitted that hypertension primarily results
from chronic hyperactivity of the sympathetic nervous system
(Gonzalez et al., 2002). There are several evidences suggest that
elevated sympathetic nerve activity results in dysregulated blood
pressure, causing chronic hypertension (Guyenet, 2006; Malpas,
2010). The central nervous system also plays a vital role in
the blood pressure regulation in hypertension. Cardiovascular
regulatory brain nuclei include the subfornical organ, PVN of
the hypothalamus, rostral ventrolateral medulla (RVLM), and
nucleus tractussolitarii of the brainstem (Ho et al., 2008; Braga
et al., 2011).
Previous work had suggested that in the rostral ventrolateral
medulla of stroke-prone spontaneously hypertensive rats, AT1R
could activate caspase-3 through the Ras/p38/ERK pathway,
which might be involved in the mechanisms underlying
sympathoexcitation and pathogenesis of hypertension (Kishi
et al., 2010). As RVLM, PVN also plays a pivotal role in regulating
blood pressure in hypertensive states (Xue et al., 2012; Su Q.
et al., 2014). Data from our lab also demonstrate there is RAS
activation in PVN of chronic renal failure rats (Cao et al., 2015).
It has been found that oxidative stress is a key mechanism
in Ang-II-dependent hypertension, and Ang-II-induced ROS
participate along the SFO-PVN-RVLM pathway in the regulation
of hypertension (Shafton et al., 1998). Of note, some parvocellular
subgroups in PVN projected to the pressor region of the RVLM
and then influenced sympathetic nerve activity. Furthermore,
Ang-II microinjected into the PVN directly caused cardiac
sympathetic activation and higher mean arterial pressure in 2-
kidney-1-clip rats than in sham rats (Han et al., 2011). Thus,
we speculated the regulatory signaling that was revealed in the
RVLM may also be activated in the PVN during pathogenesis of
hypertension (Kishi et al., 2010).
In this study, five-sixth nephrectomy was used to establish a
renal hypertension model (Badyal et al., 2003; Yamaguchi et al.,
2014). We first assessed whether RAS were activated in the PVN
of rat models by detecting the key components angiotensinogen,
Ang II and AT1R. Then we performed intracerebroventricular
(ICV) injections with AT1R antagonist (losartan), as well as Ras
(farnesylthiosalicylic acid, FTS) (Gana-Weisz et al., 1997), MEK
(PD98059, which effectively inhibits ERK1/2 phosphorylation)
(Virdee and Tolkovsky, 1996), p38 MAPK (SB203580) (Piao
et al., 2003) and caspase-3 inhibitors (Z-DEVD-FMK) (Knoblach
et al., 2004) respectively in the renal hypertension rats. Those
interventions were designed to examine whether there were
similar associations of AT1R, Ras, and MAPKs in apoptosis
regulation in the PVN as previously reported in the RVLM,
which eventually led to overactive SNA and renal hypertension.
In Figure 1, we illustrated the apoptotic pathway involved this
research and where the various inhibitors acted (Xia et al., 1995;
Downward, 1998; Braga et al., 2011).
MATERIALS AND METHODS
Animals and Grouping
All animal experiments were approved by the Institutional
Animal Care and Use Committee of Nanfang Hospital, Southern
Medical University, and carried out in accordance with the
ARRIVE guidelines (McGrath et al., 2010). The study protocol
was approved by the Ethics Committee for experimental animals,
Southern Medical University.
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FIGURE 1 | Schematic diagram illustrates the apoptotic pathway being
examined and where each drug acts. Losartan (angiotensin II receptor type
1 (AT1R) antagonist), FTS (farnesyl thiosalicylic acid, Ras inhibitor), PD98059
(MEK inhibitor), SB203580 (p38 inhibitor), Z-DEVD-FMK (caspase-3 inhibitor).
Male Sprague-Dawley rats (180–200 g) were maintained
under a 12/12 h light/dark cycle at 22◦C, and fed a standard
laboratory chow ad libitum. The animals were randomly assigned
to undergo sham operation or five-sixth nephrectomy to establish
a renal hypertension model. Briefly, two-thirds of the left kidney
was first removed; a week later, the right kidney was totally
excised under pentobarbital anesthesia. The sham group only
underwent de-capsulation of the kidneys.
Ten weeks after the final surgery, 5/6Nx rats were
randomized into 7 groups (n = 6 per group): Àno
treatment; Áintracerebroventricular injection (ICV) of artificial
cerebrospinal fluid (aCSF) as the vehicle; ÂICV of losartan
(Sigma Chemical, 2.29 mmol/l/kg), an angiotensin II subtype 1
receptor (AT1R) antagonist; ÃICV of farnesylthiosalicylic acid
(FTS) (Cayman Chemical, 1 mmol/l/kg), a Ras inhibitor; ÄICV
of 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
(PD98059) (Sigma Chemical, 200 µmol/l/kg), a selective MEK
inhibitor that effectively inhibits ERK1/2 phosphorylation;ÅICV
of 4-(4-Fluorophenyl)-2-(4-methylsulfinylpheyl)-5-(4-pyridyl)-
1H-imidazole (SB203580) (Sigma Chemical, 200 µmol/l/kg),
a p38MAP kinase inhibitor; ÆICV of N-Benzyloxycarbonyl-
Asp (OMe)-Glu (OMe)-Val-Asp- (OMe)-fluoro-methylketone
(Z-DEVD-FMK) (Calbiochem, 1500 µmol/l/kg), a caspase-3
inhibitor. Sham operated rats (n = 6) with no treatment were
used as normal controls.
ICV was performed with a stereotactic frame (David Kopf
Instrument Inc., USA) after anesthesia with 3% pentobarbital
sodium (0.15 mL/100 g body weight). A brain-infusion cannula
(Brain Infusion Kit 2; ALZET Inc., USA) coupled to an osmotic
pump (Model 2002; ALZET Inc., USA) was implanted into the
cerebral ventricle. The coordinates were −1.0 mm posterior and
1.5mm lateral from themidline, and 4.5mm ventral, with respect
to the bregma. Osmotic pumps were placed subcutaneously at the
back of the neck. Following surgery, the wounds were carefully
closed. The implanted osmotic pumps would continuously infuse
aCSF or respective drugs into the lateral cerebral ventricle at 0.5
µl/h for 14 days.
Measurements and Sample Collection
Ten weeks after the final nephrectomy or sham operation, rats
were weighted; 24-h urine samples were collected and urinary
protein excretion was assessed by the Bradford method; blood
pressure was determined with a pressure transducer (Gould)
placed in the femoral artery and connected to a physiologic
recorder (Gilson Medical Electronics) in anesthetized rats (Li
et al., 2007). Serum creatinine levels were measured on an
automatic biochemical analyzer (AU480, Beckman Coulter).
Plasma norepinephrine concentrations were assessed using a
competitive ELISA kit using TMB (3, 3, 5, 5-TetraMethyl
benzidine solution liquid MeMbrane substrate) as a substrate
and finally monitored at 450 nm. Moreover, the standard range
and the sensitivity of the kit are 0.2–32 ng/ml and 1.3 pg/ml,
respectively (Demeditec Diagnostics, DEE5200).
Two weeks after administration of aCSF or drugs, the above
measurements were performed again. Then, all animals were
anesthetized with 3% pentobarbital sodium (0.15 mL/100 g body
weight) and sacrificed by cervical dislocation.
Some rats were transcardially perfused with 200 ml ice-cold
normal saline followed by 400 ml 4% paraformaldehyde. Then,
the brains were removed and sectioned, fixed for 6 h, and
dehydrated in graded alcohol. Finally, the samples were paraffin
embedded and sliced in 5 µm sections for immunochemistry.
To identify the position of PVN, the brains were immediately
removed and1-mm thick sections were cut using a cryostat. The
PVN was defined and excised from 1-mm-sections on dry ice
based on an rat brain atlas (Paxinos and Watson, 1998; Figure
S1). PVNs were isolated from brains in accordance with the steps
above, snap frozen in liquid nitrogen, and stored at −80◦C for
protein and RNA extraction.
Immunohistochemistry and
Immunofluorescent Tunel Reaction
Immunohistochemical assessment of RAS, p-ERK1/2, and Bax
levels in PVN samples was performed with the avidin–biotin-
peroxidase complex method. Primary antibodies were mouse
anti-AGT monoclonal antibodies (1:500, Swant, Switzerland),
rabbit polyclonal antibodies raised againstangiotensin II (1:400,
Peninsula laboratories, USA), AT1R (1:100, Millipore, USA), and
Bax (1:500, Santa Cruz, USA), and rabbit monoclonal antibodies
targeting phospho-ERK1/2 (1:100, Cell Signaling Technology,
USA), respectively. Biotinylated goat anti-rabbit/mouse
secondary antibodies (1:200) were used for detection. Finally,
sections were incubated with avidin–biotin–peroxidase complex
(VECTASTAIN ABC Kit, USA) and peroxidase substrate
solution (Vector Laboratories, USA) until optimal signal
intensity developed. After dewaxing and hydration with graded
ethanol, photographs were acquired under a microscope and
analyzed using the Image-Pro Plus software. Finally, positive
cells were counted in 10 low-power field at least three slices per
group. Data were presented as positive cells per 103 µm2.
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Immunoflourescent TUNEL staining was performed by
following steps: The sections were rehydrated and treated
with 0.1% Triton-100 for 30 min at room temperature,
then applied 100 uL TUNEL reaction mix from the In Situ
Cell Death Detection Kit (Roche 11684817910) in a dark
humidified chamber at 37◦C for 60 min prior to counterstaining
tissue with 4′,6-diamidino-2-phenylindole (DAPI)
nuclear dye.
Western Blotting
PVN samples were homogenized in a lysis buffer and Western
blot was performed as previously described (Su Z. et al., 2014).
Specifically, Ras active protein (Ras-GTP) was extracted from
total tissue lysates by adding 80 ug GST-Raf1-RBD per 500
ug sample and using Active Ras Pull-Down and Detection
Kit (Thermo scientific, USA) and assessed by western blot
immediately or stored at−20◦C.
Primary antibodies used included the following: anti-
AT1-R (1:200, Millipore, USA), anti-p-ERK1/2 (1:300, Cell
Signaling Technology, USA), anti-p-p38 (1:500, Cell Signaling
Technology, USA), anti-p38 (1:1000, Cell Signaling Technology,
USA), anti-Bax (1:500, Santa Cruz Biotechnology), anti-Bcl-
2 (1:200, Santa Cruz Biotechnology), anti-Cleaved caspase-3
(1:600, Cell Signaling Technology), anti-ERK1/2 (1:1000, Cell
Signaling Technology, USA), anti-Ras (1:200, AbcamCambridge,
UK), anti-β-actin (1:5000, Cell Signaling Technology), anti-
GAPDH (1:1000, Cell Signaling Technology). The levels of
the above proteins were determined as previously described
(Su Z. et al., 2014). AT1-R protein content was normalized
to GAPDH amounts. Ras, p-ERK1/2, and p-p38 levels were
normalized to total Ras, ERK1/2 and p38, respectively. Bax,
Bcl-2 and cleaved caspase-3 protein levels were normalized to
β-actin.
Real-Time PCR
Total RNA from PVN samples was extracted with TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions.
RNA concentrations were measured on a Nanodrop ND1000
spectrophotometer (NanoDrop technologies, Wilmington, DE,
USA). Reverse transcription was performed with a One-Step RT-
PCR kit (TaKaRa, Kyoto, Japan) according to the manufacturer’s
protocol. Quantitative real-time PCR was performed in a total
volume of 25 µl in duplicate on a Fast Real-Time PCR system
7500 (Applied Biosystems, CA, USA) with the SYBR Premix
Ex Taq kit (TaKaRa, Kyoto, Japan). Thermal cycling conditions
comprised 30 s at 95◦C, followed by 95◦C for 5 s, 60◦C for 30 s,
and 72◦C for 60 s for 40 cycles. The relative expression levels of
targeted mRNAs were calculated after normalization to GAPDH
mRNA using the 2−11CT method. The primer sets used are
summarized in Table 1.
Statistical Analysis
All analyses were performed with SPSS 19.0 for Windows. Data
are mean ± standard error of the mean (SEM). Continuous
variables between groups were compared by one-way analysis of
variance, followed by Least Significant Difference (LSD test). The
level of statistical significance was set at 0.05.
TABLE 1 | Primers used for quantitative Real-time PCR.
Forward Reverse
AT1R 5′-CAGTGTGCGCGTTTCA
TTATG-3′
5′-TGGTAAGGCCCAGCCC
TAT-3′
Bax 5′-TGGTTGCCCTTTTCTAC
TTTG-3′
5′-GAAGTAGGAAAGGAGG
CCATC-3′
Bcl-2 5′-CTGGTGGACAACATCG
CTCTG-3′
5′-GGTCTGCTGACCTCAC
TTGTG-3′
GAPDH 5′-TGCCAAGTATGATGAC
ATCAAGAA-3′
5′-AGCCCAGGATGCCCTT
TAGT-3′
RESULTS
Successful Establishment of a Rat Model
of Chronic Renal Hypertension
Ten weeks after the 5/6 nephrectomy (5/6 Nx), body weight,
24 h urinary protein excretion, systolic blood pressure, serum
creatinine, and plasma norepinephrine in model rats were
evaluated, in comparison with sham-operated controls (Table S1,
p< 0.05). Plasma norepinephrine concentrations were used as an
indicator of sympathetic nerve activity (Zoccali et al., 2002). As
shown in Table S1, 5/6Nx rats showed similar body weights, but
significantly higher 24 h urine protein excretion as well as systolic
blood pressure, serum creatinine, and plasma norepinephrine
(p < 0.05). These findings indicated a successful establishment
of a rat model of chronic renal hypertension.
General Characteristics of the
Hypertensive Animals after 14 Days of
Treatment with Various Agents
There were no differences among rats with renal hypertension
administered aCSF and various agents, in body weight and
serum creatinine (Table 2, p < 0.05). Compared with the
aCSF group, intracerebroventricular injection with losartan,
FTS, PD98059, and Z-DEVD-FMKICV resulted in significantly
decreased urinary protein, systolic blood pressure and plasma
norepinephrine levels (Table 2, p < 0.05). However, the
p38 inhibitor SB203580 showed no effects on the above
parameters.
AT1R, Ras-GTP, p-ERK1/2, and p-p38
Levels in PVN Specimens from Model and
Sham-Operated Rats
Immunochemistry, western blot and real-time PCR were used
to assess the expression of AGT, Ang II, and AT1R. Compared
with the values obtained for sham-operated rats, AGT, Ang II,
and AT1R amounts in PVN from rats with renal hypertension
were significantly higher (Figures 2A–D, p < 0.05). Western
blot and immunochemistry were used to detect Ras-GTP, p-
ERK1/2, and p-p38. Compared with sham-operated rats, the
model animals showed significantly higher Ras-GTP, p-ERK1/2
and p-p38 protein levels in PVN samples (Figures 2E–H,
p< 0.05).
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TABLE 2 | General characteristics before and after 14 days of blockade with various approaches in renal hypertension rats or sham ratsA.
Group BW SBP Scr UPE Plasma NE
Sham 5/6Nx 495.6 ± 5.0 124.7 ± 3.2 41.9 ± 0.6 8.6 ± 0.5 235.4 ± 21.9
10 weeks 538.3 ± 10.4 148.8 ± 2.1B 106.6 ± 7.2B 28.7 ± 3.0B 589.5 ± 17.0B
12 weeks 498.6 ± 7.9 150.3 ± 3.2B 105.7 ± 8.2B 22.4 ± 1.8B 655.0 ± 37.0B
5/6Nx+ i.c.v. aCSF 489.7 ± 6.8 146.0 ± 2.1B 106.9 ± 7.2B 22.4 ± 1.2B 608.1 ± 48.1B
5/6Nx+ Losartan 490.0 ± 3.5 119 ± 1.5C 100.4 ± 2.8 11.6 ± 0.8C 302.1 ± 3.0C
5/6Nx+ FTS 493.3 ± 2.9 119 ± 2.3C 106.1 ± 6.6 12.2 ± 0.6C 276.5 ± 23.2C
5/6Nx+ PD98059 490.7 ± 4.5 122.0 ± 2.1C 100.9 ± 2.2 12.7 ± 0.4C 240.7 ± 15.4C
5/6Nx+ SB203580 496.0 ± 5.2 140.7 ± 0.89 104.7 ± 9.0 21.9 ± 1.6 573.4 ± 30.2
5/6Nx+ Z-DEVD-FMK 501.0 ± 7.1 128.8 ± 2.2C 103.3 ± 9.1 12.2 ± 0.4C 312.5 ± 26.1C
A Data from 3 independent experiments are expressed as mean ± SD (n = 6 for each group). B p < 0.05 vs. Sham group, C p < 0.05 vs. 5/6Nx + i.c.v CSF group. 5/6 Nx: five-sixth
nephrectomy; BW, body weight; SBP, systolic blood pressure; Scr, serum creatinine; UPE, urinary protein excretion; Plasma NE, Plasma norepinephrine. Losartan (angiotensin II receptor
type 1 (AT1R) antagonist), FTS (farnesyl thiosalicylic acid, Ras inhibitor), PD98059 (MEK inhibitor), SB203580 (p38 inhibitor), Z-DEVD-FMK (caspase-3 inhibitor).
FIGURE 2 | Expression levels of AGT, AngII, AT1R, Ras-GTP, p-ERK, and p-p38 in PVN of sham-operated and 5/6Nx rats. (A) Representative
immunochemistry micrographs of samples from sham and 5/6Nx groups for AGT, AngII, and AT1R respectively (PVN nucleus in this picture was circled by dotted line).
(B) Representative quantitative statistics of samples of sham and 5/6Nx groups for AGT, AngII, and AT1R, respectively. (C,D) Representative protein expression and
mRNA level of AT1R were assessed in sham and 5/6Nx groups, by RT-PCR and western blot, with GADH used for normalization. (E,F) Ras-GTP and total Ras protein
expression levels assessed by western blot and immunohisochemistry technique in sham and 5/6Nx groups, respectively. (G,H) p-ERK 1/2, ERK 1/2, p-P38, and P38
protein expression levels in sham and 5/6Nx groups. Data are mean ± SEM (n = 6 per group). *p < 0.05 vs. sham group. 5/6 Nx: five-sixth nephrectomy.
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Neuronal Apoptosis in PVN Specimens
from Model and Sham-Operated Rats
Immunochemistry, western blot and real-time PCR showed that
cleaved caspase-3 and Bax amounts in PVN from model rats
were significantly higher compared with the values obtained
for sham-operated rats Bcl-2 expression was reduced in the
model rats, both at the gene and protein levels, although
the latter did not reach statistical significance (Figures 3A–D,
p < 0.05). TUNEL staining is a well-defined method for
detecting apoptotic DNA fragmentation in tissue. Figure 3E
demonstrated that TUNEL-positive cells apparently increased
in the hypothalamus PVN of 5/6Nx rats compared to
sham rats.
The observations after nephrectomy and subsequent drug
treatments suggested that increased apoptosis of central nervous
system neurons may play a crucial role in elevating blood
pressure in case of kidney damage, possibly by relieving the
constraints on the sympathetic nervous system; upregulated
AT1R, Ras, ERK1/2, and caspase-3 signaling pathways in the CNS
may constitute the underlyingmechanisms at themolecular level.
However, p38 MAPK activation appeared to play no decisive role
in hypertension.
Regulatory Associations of RAS, Ras, and
ERK with Apoptosis in the PVN from Rats
with Renal Hypertension
To determine the possible regulation mechanism of AT1R
on blood pressure and sympathetic nerve activity, AT1R
protein expression in PVN of rats with renal hypertension
was assessed after intracerebroventricular injection with aCSF,
losartan, FTS, PD98059, and Z-DEVD-FMK, by western blot.
Interestingly, high AT1R levels in PVN of model rats were
decreased only by ICV losartan (p < 0.05). Meanwhile,
FTS, PD98059, SB203580, and Z-DEVD-FMK administered
by ICV showed no effects on AT1R protein expression
(Figure 4A).
Meanwhile, Ras activity was significantly lower in samples
from model groups treated (ICV) with losartan and FTS (p <
0.05); however, ICV treatment with PD98059, SB203580, and
Z-DEVD-FMK yielded no effects on Ras activity (Figure 4B).
These findings demonstrated that AT1R regulated Ras activity,
with the remaining blocking agents failing, in the PVN of rats
with renal hypertension.
Interestingly, ERK1/2 phosphorylation was significantly
lower in PVN samples from model rats that received ICV
FIGURE 3 | Apoptosis markers’ change in PVN samples from rats with renal hypertension and sham operation. (A) C-caspase-3 protein levels in sham and
5/6Nx rats. (B) Bax and Bcl-2 protein levels in sham and 5/6Nx rats. (C) Representative immunochemistry micrographs and quantitative statistics of Bax in sham and
5/6Nx groups. (PVN nucleus in this picture was circled by dotted line). (D) Bax and bcl-2 mRNA levels in sham and 5/6Nx groups, by real-time PCR, with GADH used
for normalization. (E) TUNEL staining in sham and 5/6Nx groups (PVN nucleus in this picture was circled by dotted line). Data are mean ± SEM (n = 6 per group).
*p < 0.05 vs. sham group. 5/6 Nx: five-sixth nephrectomy. C-caspase-3, cleaved-caspase-3.
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FIGURE 4 | Protein levels RAS, Ras, ERK, and apoptosis markers in PVN samples after 14 days of blockade with various approaches in renal
hypertension and sham rats. (A) AT1R protein levels in sham and 5/6Nx rats treated with intracerebroventricular injection (ICV) various inhibitors. (B) Ras-GTP and
total Ras protein levels in sham and 5/6Nx rats treated with intracerebroventricular injection (ICV) various inhibitors. (C) p-ERK1/2 and ERK 1/2 protein levels in sham
and 5/6Nx rats treated with intracerebroventricular injection (ICV) various inhibitors. (D) Cleaved caspase-3 protein levels in sham and 5/6Nx rats treated with
intracerebroventricular injection (ICV) various inhibitors. (E) Bax protein levels in sham and 5/6Nx rats treated with intracerebroventricular injection (ICV) various
inhibitors. (F) Bcl-2 protein levels in sham and 5/6Nx rats treated with intracerebroventricular injection (ICV) various inhibitors. Data are mean ± SEM (n = 6 per group).
*p < 0.05 vs. sham group; #p < 0.05 vs. 5/6Nx+aCSF group. Losartan (Angiotensin II receptor type 1 (AT1R) antagonist), FTS (farnesyl thiosalicylic acid, Ras
inhibitor), PD98059 (MEK inhibitor), SB203580 (p38 inhibitor), Z-DEVD-FMK (caspase-3 inhibitor).
injection of losartan, FTS, and PD98059 (p < 0.05), with
SB203580 and Z-DEVD-FMK showing no effects on ERK1/2
activity (Figure 4C). These findings demonstrated that both
AT1R and Ras regulated ERK1/2 phosphorylation, unlike the
remaining blocking agents, in the PVN of rats with renal
hypertension.
The effects of these blocking agents were evaluated onmarkers
of cell apoptosis. As shown in Figure 4, Bax and cleaved caspase-
3 levels were significantly higher in PVN samples from model
rats compared with Sham-operated animals, while Bcl-2 amounts
were significantly lower. Meanwhile ICV injection of losartan,
FTS, and PD98059 in rats with renal hypertension significantly
reduced Bax amounts, and markedly increased Bcl-2 levels.
In addition, ICV injection of losartan, FTS, PD98059, and Z-
DEVD-FMK in rats with renal hypertension significantly reduced
cleaved caspase-3 amounts (Figures 4D–F, p< 0.05).
DISCUSSION
This study demonstrated that chronic renal disease
due to nephrectomy would lead RAS activation in
PVN of the hypothalamus, which further induced
neuronal apoptosis through the Ras/ERK1/2 signaling
pathway. The neuronal apoptosis in PVN may deregulate
sympathetic activity and bring about renovascular
hypertension.
Brain RAS in blood pressure regulation have attracted more
and more attention for decades. It has been shown that AT1R
expression increased in the cardiovascular regulatory region,
with an enhanced sensitivity to Ang II in animal models with
neurogenic hypertension (Xia et al., 2013). Hyperactivity of Ang
II/AT1R in the CNS leads to neurogenic hypertension (Biancardi
et al., 2014). In the present study, excessive activation of RAS
was found in the PVN from renal hypertensive rats, as reflected
by increased expression levels of AGT, Ang II, and AT1R. And
blocking the brain RAS with AT1R antagonist losartan could
provide relief from high systolic blood pressure. These findings
were in accordance with our previous work concerning the
relation of RAS activation in PVN and chronic renal failure. We
has also demonstrated that increased central oxidative stress
leads to an increase in sympathetic activity, and blockade of
oxidative stress with intracerebroventricular administration of
antioxidant tempol reduced sympathetic activity in rats with
chronic renal failure fed with high salt diet (Cao et al., 2015).
In addition, Braga et al. reported that chronic peripheral Ang-II
infusion in mice produces a slow developing hypertension, which
is accompanied by superoxide accumulation in the RVLM and
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increased sympathetic activity (Braga et al., 2011). Furthermore,
norepinephrine, which is a biomarker of sympathetic activation,
stimulated apoptosis in adult rat ventricular myocytes
in vitro (Communal et al., 1998). Thus, Ang-ROS pathway
may increase sympathetic activity which finally result in
apoptosis.
In vitro experiments had suggested that Ang II activation
is responsible for apoptosis and proliferation of endothelial
and epithelial cells in a model of malignant hypertension
(Efrati et al., 2007). Ang II was also found to play a critical
role in the development of renal cell apoptosis in Ang II-
infused hypertension, while losartan decreases apoptosis (Aizawa
et al., 2001). In addition, our study explored the relationship
of RAS activation and elevated apoptosis in the context
of nervous system cells. We discovered that hypertensive
rats showed pro-apoptotic mechanism activation in PVN, as
reflected by increased levels of Bax and caspase-3, decreased
amount of Bcl-2, and elevated TUNEL-positive cells, which
suggested neuronal loss in PVN after 5/6Nx operation. And
the fact that intracerebral injection of Z-DEVD-FMK could
reduce blood pressure and lowered plasma norepinephrine level
had clearly indicated the PVN apoptosis induced by AT1R
activation made important contributions to pathogenesis of
renal hypertension, possibly through increasing sympathetic
activity.
This study also showed that Ras, p-ERK1/2 (p44/42 MAPK)
and p38 MAPK signaling were all activated in the PVN
of rats with renal hypertension. The MEK/ERK1/2 signaling
plays an important role in the regulation of the renin-
angiotensin system toward the sympathetic nervous system,
in the brain of heart failure rats (Wei et al., 2008b). This
role of ERK1/2 in Ang II-induced hypertension was further
demonstrated by the observation that injection of the MEK
inhibitor PD98059 bilaterally into the RVLM dramatically
lowers Ang II-infused hypertension (Seyedabadi et al., 2001). In
other words, hypertension resulted from RAS activation in the
ventrolateral medulla is dependent on ERK1/2 phosphorylation.
Our research work discovered that for the central nervous
regulation of sympathetic activity and blood pressure in
PVN, p-ERK1/2 was also essential in bridging RAS activation
and hypertension development; while the increase of p-p38
appeared only the concomitant consequence but not the decisive
factor. Another study had showed that MAPK pathway in
turn plays an important role in up-regulation of AT1R (Wei
et al., 2008a). Yet, we found in the renal hypertensive rat
model, the positive regulation of AT1R toward p-ERK1/2 was
unidirectional.
Ras proteins are expressed in almost all cell types, including
fibroblasts and muscle cells, and activate signal transduction
pathways that regulate cellular proliferation, differentiation, and
survival (Schwartz et al., 2007). In a study assessing non-
small cell lung cancer (Pelaia et al., 2012), Ras inhibitors
were found to inhibit ERK1/2 activation and apoptosis.
What’s more, previous work had illustrated that the MAPK
pathway induced by Ras was involved in apoptosis regulation
of RVLM, which resulted in sympathetic overactivity and
hypertension development upon AT1R activation (Kishi et al.,
2010). The present study revealed similar associations of
AT1R, Ras, and ERK1/2 in apoptosis regulation of the PVN
as in the RVLM, while with regard to the pathogenesis
of renal hypertension rather than stroke-prone spontaneous
hypertension.
The present study has some limitations. After 2-week infusion
of drugs in PVN, the SNA and blood pressure was decreased
by ICV infusion of the AT1R antagonist, Ras inhibitor, MEK
inhibitor, and caspase-3 inhibitor, but we did not assess the
changes in RVLM, which may also be important to the regulation
of renal hypertension. Therefore, we cannot exclude the effects
of these drugs in other brain sites, and the role of other
autonomic nuclei in neural control of SNA and blood pressure
needs further study. In addition, we did not measure the
concentrations of ICV infused drugs in the blood, and thus
cannot exclude some spillover effects in the periphery. However,
the ICV dosage of losartan were >500-fold lower than the
dose commonly used in the periphery by gastrogavage and were
chosen from preliminary studies in which intravenous injection
of these doses had no detectable effects on AngII-induced
increase in blood pressure or circulating norepinephrine levels
(Cao et al., 2015).
Taken together, our findings suggested that RAS system
mainly composed of angiotensinogen, Ang II, AT1R, was
activated in the PVN of renal hypertensive rats; those changes
would mediate neuronal apoptosis through the Ras/ERK1/2
pathways, regulating sympathetic activity and blood pressure,
which played a crucial role in the pathogenesis of renal
hypertension. Inhibition by intracerebroventricular infusion of
ARB in the PVN may be a novel therapeutic approach to
sympathoexcitation in hypertension. Moreover, angiotensin II
and ROS are important modulating factors regulating SNA,
which is involved in hypertension and heart failure. We consider
that neural apoptosis in the PVN is a novel target for the
treatment of cardiovascular diseases exhibiting increased SNA
and blood pressure.
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